HC Wainwright Estimates Rezolute FY2030 Earnings

Key Points

• HC Wainwright projects that Rezolute will achieve FY2030 earnings of $0.61 per share, maintaining a "Buy" rating and a $14.00 price target, despite the current consensus of a loss of ($0.93) per share.
• Shares of Rezolute are trading around $8.20, experiencing a 52-week low of $2.21 and a high of $8.34.
• Institutional investors hold 82.97% of Rezolute's stock, with several companies, including BNP Paribas and Ameritas, recently acquiring new stakes in the company.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Rezolute in a report issued on Thursday, September 18th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of $0.61 per share for the year. HC Wainwright has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share.

Several other research analysts have also weighed in on the stock. Guggenheim restated a "buy" rating and set a $15.00 price objective on shares of Rezolute in a research note on Monday. Maxim Group boosted their price objective on shares of Rezolute from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday. BTIG Research restated a "buy" rating and set a $17.00 price objective on shares of Rezolute in a research note on Thursday, September 18th. Finally, Wedbush restated an "outperform" rating and set a $12.00 price objective on shares of Rezolute in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $14.50.

Rezolute Trading Up 4.1%

Shares of Rezolute stock traded up $0.33 during trading on Friday, hitting $8.47. 558,918 shares of the stock were exchanged, compared to its average volume of 955,411. The stock has a market capitalization of $769.16 million, a price-to-earnings ratio of -8.72 and a beta of 0.02. The company has a fifty day moving average price of $6.68 and a 200-day moving average price of $4.77. Rezolute has a 1-year low of $2.21 and a 1-year high of $8.81.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Wednesday, September 17th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.03).

Institutional Trading of Rezolute

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Federated Hermes Inc. lifted its holdings in shares of Rezolute by 24.4% during the 2nd quarter. Federated Hermes Inc. now owns 14,034,712 shares of the company's stock worth $62,595,000 after acquiring an additional 2,755,385 shares during the period. Marshall Wace LLP lifted its holdings in shares of Rezolute by 56.4% during the 2nd quarter. Marshall Wace LLP now owns 2,886,481 shares of the company's stock worth $12,874,000 after acquiring an additional 1,041,234 shares during the period. Nantahala Capital Management LLC lifted its holdings in shares of Rezolute by 77.4% during the 2nd quarter. Nantahala Capital Management LLC now owns 2,291,395 shares of the company's stock worth $10,220,000 after acquiring an additional 1,000,000 shares during the period. Affinity Asset Advisors LLC lifted its holdings in shares of Rezolute by 29.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 2,200,000 shares of the company's stock worth $9,812,000 after acquiring an additional 500,000 shares during the period. Finally, Rosalind Advisors Inc. bought a new stake in shares of Rezolute during the 2nd quarter worth approximately $7,766,000. Institutional investors own 82.97% of the company's stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.